Patent: 6,479,512
✉ Email this page to a colleague
Summary for Patent: 6,479,512
Title: | Tyrosine kinase inhibitors |
Abstract: | The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. |
Inventor(s): | Fraley; Mark E. (North Wales, PA), Hambaugh; Scott R. (Norristown, PA), Hungate; Randall W. (Lansdale, PA) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Application Number: | 09/690,602 |
Patent Claims: | see list of patent claims |
Details for Patent 6,479,512
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2039-02-26 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |